Benefits
Reduced T2DM risk in epidemiological studies
Large European prospective cohort studies found a strong inverse association between dietary myricetin intake and type 2 diabetes risk — myricetin showed the most pronounced inverse relationship among flavonols (vs isorhamnetin, kaempferol, quercetin), and Finnish cohorts confirmed a similar association. Critical caveat: dietary observational data does not establish causality — high-myricetin diets correlate with healthier overall eating patterns (more fruits, vegetables, tea, walnuts).
Multifunctional anti-diabetic mechanisms (preclinical)
Myricetin demonstrates multiple complementary mechanisms relevant to T2DM in preclinical models: (1) inhibits intestinal glucose absorption (α-glucosidase inhibition), (2) enhances insulin secretion (possibly via GLP-1 receptor modulation), (3) protects pancreatic β-cells from oxidative stress and CDK5-mediated dysfunction, (4) directly modulates GLUT4 in muscle/adipose, (5) ameliorates insulin resistance. Multimechanism profile theoretically attractive but human RCT validation absent.
Antioxidant and anti-inflammatory
The 6-hydroxyl flavonol structure provides exceptional radical scavenging capacity — myricetin is among the more potent dietary flavonoid antioxidants in vitro. Inhibits NF-κB, reducing pro-inflammatory cytokines. Mechanism for many traditional and modern anti-inflammatory claims.
Cardiovascular effects (preclinical, dietary)
Animal and dietary studies suggest myricetin reduces atherosclerosis development by reducing macrophage accumulation in lesions, improves endothelial function, and supports lipid profile. Mechanism via antioxidant + anti-inflammatory effects on vascular wall. Human pharmacological RCT evidence specific to purified myricetin is absent.
Antiviral activity (in vitro broad spectrum)
Myricetin shows in vitro activity against HIV-1 reverse transcriptase, influenza, herpesviruses, and SARS-CoV-2 helicase. During COVID-19 pandemic, myricetin received attention as potential SARS-CoV-2 antiviral. Human clinical trial data limited; molecular mechanism interesting but translation incomplete.
Mechanism of action
α-Glucosidase inhibition
Myricetin competitively inhibits α-glucosidase (intestinal carbohydrate-digesting enzyme) — slowing glucose release from complex carbohydrates and reducing postprandial glucose spike. Mechanism similar to acarbose drug class. May contribute to T2DM-related epidemiological associations.
GLP-1 receptor activation (proposed)
Some preclinical evidence suggests myricetin acts as GLP-1 receptor agonist or modulator — enhancing insulin secretion in glucose-dependent manner. Mechanism analogous to liraglutide/semaglutide drug class. Direct receptor binding evidence limited; clinical relevance unclear.
Direct radical scavenging via 6-OH structure
Myricetin's 6 hydroxyl groups provide exceptional antioxidant capacity through hydrogen donation and chelation of pro-oxidant metal ions. Among the most polyhydroxylated common flavonols. Mechanism for broad antioxidant effects across tissue types.
GLUT4 modulation in adipocytes/myocytes
Direct interaction with glucose transporter type 4 (GLUT4) in adipose tissue and muscle — facilitating insulin-stimulated glucose uptake. Mechanism for insulin sensitization independent of insulin secretion or absorption effects. Adds to multifunctional T2DM-relevant profile.
β-cell protection via CDK5 inhibition
Myricetin inhibits cyclin-dependent kinase 5 (CDK5) in pancreatic β-cells — preventing β-cell dysfunction in hyperglycemic conditions. Mechanism for preserving insulin secretion capacity over time.
Clinical trials
Large prospective European cohort study (Zamora-Ros R et al. 2014, J Nutr 144(3):335-343, doi:10.3945/jn.113.184945).
Case-cohort study within EPIC-InterAct: ~26,000 incident T2DM cases vs ~16,000 sub-cohort participants across 8 European countries. Dietary flavonoid intake assessed via dietary questionnaires.
Strong inverse association between myricetin intake and T2DM risk — myricetin showed the most pronounced inverse relationship among flavonols (vs kaempferol, quercetin, isorhamnetin). Hazard ratio reduced significantly in highest vs lowest intake quintile. Critical caveat: observational/epidemiological — does not establish causality. High-myricetin diets reflect overall healthy eating patterns (fruits, vegetables, walnuts, tea, red wine).
Comprehensive review (Semwal DK, Semwal RB, Combrinck S, Nutrients 8(2):90, doi:10.3390/nu8020090)./.
Review of myricetin's preclinical pharmacological activities and limited clinical studies.
Documented antioxidant, anti-inflammatory, antiplatelet, antihypertensive, immunomodulatory, anti-allergic, analgesic, anticancer activities in preclinical models. Limited clinical trials. Authors noted substantial gap between extensive preclinical evidence and absence of rigorous human clinical trials. Average dietary intake estimates (0.8-2 mg/day) suggest pharmacological doses would require supplementation.
Evidence review and pooled analysis (Mock K et al. 2024, Nutrients 16(21):3730, doi:10.3390/nu16213730).
Evidence review and pooled analysis (PROSPERO) of in vivo mouse studies of myricetin in metabolic disease models. Embase, Scopus, PubMed, Web of Science searched through.
Pooled analysis of mouse studies showed myricetin supplementation reduced blood glucose, improved insulin sensitivity, reduced TAG and total cholesterol, and improved HDL/LDL ratios. Critical caveat: preclinical only — direct human translation requires rigorous human clinical trials that have not yet been done in adequate sample sizes. Supports moving forward with human trials but not direct clinical recommendations.